Media headlines about SAGE Therapeutics (NASDAQ:SAGE) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SAGE Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 44.9006866800046 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Sage Therapeutics, Inc. (NASDAQ:SAGE) – Hair-Raising Facts to Know – Nasdaq Journal (press release) (nasdaqjournal.com)
- Sage Therapeutics to Present at JP Morgan Healthcare Conference on Tuesday, January 9, 2018 – Business Wire (press release) (businesswire.com)
- Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 (finance.yahoo.com)
- 7 Notable Biotechs With Data Expected By Year’s End (finance.yahoo.com)
SAGE Therapeutics (SAGE) traded down $3.73 on Thursday, reaching $166.44. The company had a trading volume of 380,700 shares, compared to its average volume of 1,060,000. SAGE Therapeutics has a 1 year low of $44.55 and a 1 year high of $173.36. The firm has a market cap of $6,830.00, a PE ratio of -24.23 and a beta of 3.05.
SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.98) by $0.01. SAGE Therapeutics’s revenue was up .0% compared to the same quarter last year. research analysts expect that SAGE Therapeutics will post -7.42 EPS for the current fiscal year.
A number of equities research analysts have recently weighed in on the company. Chardan Capital reaffirmed a “hold” rating on shares of SAGE Therapeutics in a research note on Wednesday, September 13th. Canaccord Genuity set a $191.00 price objective on SAGE Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 7th. Needham & Company LLC lifted their price objective on SAGE Therapeutics from $86.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, November 10th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $203.00 price objective on shares of SAGE Therapeutics in a research note on Thursday, December 7th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $87.00 price objective on shares of SAGE Therapeutics in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $171.21.
In related news, insider Albert Robichaud sold 60,000 shares of the business’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the transaction, the insider now directly owns 152,759 shares of the company’s stock, valued at approximately $24,354,367.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the business’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $157.45, for a total value of $33,103,390.15. Following the transaction, the chief executive officer now directly owns 211,473 shares of the company’s stock, valued at $33,296,423.85. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2018/01/05/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-sage-therapeutics-sage-stock-price.html.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.